Testing BL-M11D1 for patients with relapsed or refractory acute myeloid leukemia

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients

This study is testing a new treatment called BL-M11D1 to see if it is safe and tolerable for patients with relapsed or refractory acute myeloid leukemia.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 130 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. (Industry-sponsored)
• Drugs / interventions: chemotherapy, immunotherapy
• Locations: 8 sites (Hefei, Anhui and 7 other locations)
• Trial ID: NCT05924750 on ClinicalTrials.gov

What this trial studies

This study evaluates the safety and tolerability of a new treatment called BL-M11D1 in patients suffering from relapsed or refractory acute myeloid leukemia (R/R AML). The trial is divided into two phases: Phase Ia focuses on determining the maximum tolerated dose and any dose-limiting toxicities, while Phase Ib will further assess the safety at the recommended dose established in Phase Ia. The goal is to establish a recommended dose for future studies.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 75 with confirmed relapsed or refractory acute myeloid leukemia.

Not a fit: Patients with acute myeloid leukemia who are not relapsed or refractory, or those with severe comorbidities may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with difficult-to-treat R/R AML.

How similar studies have performed: While this approach is novel, similar studies targeting R/R AML have shown promise in exploring new treatment options.

Eligibility criteria

Inclusion Criteria:

1. Voluntarily sign the informed consent form and comply with the protocol requirements;
2. No gender restrictions;
3. Age: ≥18 years and ≤75 years;
4. Expected survival time ≥3 months;
5. Histologically and/or cytologically confirmed CD33-positive relapsed/refractory acute myeloid leukemia (AML);
6. Morphological assessment showing ≥5% blasts in the bone marrow;
7. ECOG performance status score ≤2;
8. Peripheral blood white blood cell count ≤25×10\^9/L before the first dose;
9. Toxicity from prior anti-tumor therapy has recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;
10. Organ function levels meet the requirements within 7 days before the first dose;
11. For premenopausal women with childbearing potential, a pregnancy test (serum/urine) must be performed within 7 days before starting treatment, and the result must be negative; they must not be breastfeeding. All enrolled patients (regardless of gender) must use adequate barrier contraception throughout the treatment period and for 6 months after treatment ends.

Exclusion Criteria:

1. Acute promyelocytic leukemia, acute transformation of chronic myeloid leukemia.
2. Antineoplastic therapy, including chemotherapy, biologic therapy, immunotherapy, definitive radiotherapy, major surgery (investigator-defined), or targeted therapy (including small-molecule tyrosine kinase inhibitors), has been administered within 4 weeks or 5 half-life cycles (whichever is shorter) before the first dose; Or palliative radiotherapy within 2 weeks before the first dose.
3. History of severe heart disease, such as left ventricular ejection fraction \< 50%, history of symptomatic congestive heart failure (CHF) ≥ grade 2 (CTCAE v5.0), New York Heart Association (NYHA) ≥ grade 2 heart failure, history of myocardial infarction, unstable angina, etc.
4. Prolonged QT interval (QTc \> 450 msec in men or QTc \> 470 msec in women), complete left bundle branch block, and III degree atrioventricular block.
5. Active autoimmune diseases and inflammatory diseases, such as systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory intestinal diseases and Hashimoto's thyroiditis, etc., excluding type I diabetes mellitus, hypothyroidism that can only be controlled by replacement therapy, and skin diseases without systemic treatment (such as vitiligo and psoriasis).
6. Other malignancies diagnosed within 5 years before the first dose, except for radical basal cell carcinoma, squamous cell carcinoma, and/or radical resection carcinoma in situ.
7. Poorly controlled hypertension (systolic blood pressure \&gt; 150 mmHg or diastolic blood pressure \&gt; 100 mmHg).
8. Patients with pulmonary disease grade ≥3 defined by CTCAE v5.0, current or previous interstitial lung disease (ILD).
9. Patients with central nervous system involvement.
10. Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any of the ingredients of BL-M11D1.
11. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
12. Human immunodeficiency virus (HIVAb) positive, active tuberculosis, active hepatitis B virus infection (HBsAg positive; HBcAb positive and HBV-DNA copy number \> lower detection limit) or active hepatitis C virus infection (HCV antibody positive and HCV-RNA \> lower detection limit).
13. Active infection requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc.
14. Presence of pleural, abdominal, pelvic or pericardial effusion with clinical symptoms or requiring repeated drainage.
15. Had participated in another clinical trial within 4 weeks before the first dose (calculated from the time of last dose).
16. Pregnant or lactating women.
17. Other conditions for participation in the trial were not considered appropriate by the investigator.

Where this trial is running

Hefei, Anhui and 7 other locations

• Anhui Provincial Hospital — Hefei, Anhui, China (Not_yet_recruiting)
• Beijing Hospital — Beijing, Beijing Municipality, China (Not_yet_recruiting)
• Institute of Hematology, the First Hospital of Harbin — Haerbin, Heilongjiang, China (Not_yet_recruiting)
• Shengjing Hospital of China Medical University — Shenyang, Liaoning, China (Not_yet_recruiting)
• Qilu Hospital of Shandong University — Jinan, Shangdong, China (Not_yet_recruiting)
• Shanghai Tongji Hospital — Shanghai, Shanghai Municipality, China (Not_yet_recruiting)
• West China Hospital，Sichuan University — Chengdu, Sichuan, China (Not_yet_recruiting)
• Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences — Tianjin, Tianjin Municipality, China (Recruiting)

Study contacts

• Principal investigator: Junyuan Qi, PHD — Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
• Study coordinator: Sa Xiao, PHD

Conditions Relapsed/Refractory Acute Myeloid Leukemia